Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data

References

• National Cancer Institute. Cancer Stat Facts: Prostate Cancer Bethesda, MD2018 [cited 2018 May 8]. Available from: https://seer.cancer.gov/statfacts/html/prost.html
   Google Scholar
• Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17:S72–S79.
   PubMed Web of Science ®Google Scholar
• Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180–1192.
   PubMed Web of Science ®Google Scholar
• Afshar M, Evison F, James ND, et al. Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: a tertiary academic center experience. Urol Oncol. 2015;33:338.e1–7.
   Google Scholar
• Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578–583.
   PubMed Web of Science ®Google Scholar
• Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: a review. Crit Rev Oncol Hematol. 2005;56:365–378.
   PubMed Web of Science ®Google Scholar
• Terada N, Akamatsu S, Kobayashi T, et al. Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2017; 9:565–573.
   PubMed Web of Science ®Google Scholar
• Rodrigues G, Warde P, Pickles T, et al. Pre-treatment risk stratification of prostate cancer patients: A critical review. CUAJ. 2012;6:121–127.
   Web of Science ®Google Scholar
• Reese AC, Pierorazio PM, Han M, et al. Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology. 2012;80:1075–1079.
   PubMed Web of Science ®Google Scholar
• Ross-Adams H, Lamb AD, Dunning MJ, et al. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine. 2015;2:1133–1144.
   PubMed Web of Science ®Google Scholar
• Ecke TH, Schlechte HH, Schiemenz K, et al. TP53 gene mutations in prostate cancer progression. Anticancer Res. 2010;30:1579–1586.
   PubMedGoogle Scholar
• Ming M, He Y-Y. PTEN in DNA damage repair. Cancer Lett. 2012;319:125–129.
   PubMed Web of Science ®Google Scholar
• Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161:1215–1228.
   PubMed Web of Science ®Google Scholar
• Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. JCO. 2013; May 1031:1748–1757.
   PubMed Web of Science ®Google Scholar
• Chaux A, Peskoe SB, Gonzalez-Roibon N, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol. 2012;25:1543–1549.
   PubMed Web of Science ®Google Scholar
• Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697–1708.
   PubMed Web of Science ®Google Scholar
• Annala M, Struss WJ, Warner EW, et al. Treatment outcomes and tumor loss of heterozygosity in germline DNA repair-deficient prostate cancer. Eur Urol. 2017;72:34–42.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Shaukat F, Isaacsson Velho P, et al. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur Urol. 2019;75:378–382.
   PubMed Web of Science ®Google Scholar
• Isaacsson Velho P, Qazi F, Hassan S, et al. Efficacy of Radium-223 in Bone-metastatic Castration-resistant prostate cancer with and without homologous repair gene defects. Eur Urol. 2019;76:170–176.
   PubMed Web of Science ®Google Scholar
• Marshall CH, Fu W, Wang H, et al. Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage. Prostate Cancer Prostatic Dis. 2018.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Luber B, et al. Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide. Eur Urol. 2018;74:218–225.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent Small-cell neuroendocrine prostate cancer: a Multi-institutional prospective study. JCO. 2018;36:2492–2503.
   PubMed Web of Science ®Google Scholar
• Nombela P, Lozano R, Aytes A, et al. BRCA2 and other DDR genes in prostate cancer. Cancers. 2019;11:352.
   PubMed Web of Science ®Google Scholar
• Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. 2019;79:880–895.
   PubMed Web of Science ®Google Scholar
• Na R, Zheng SL, Han M, et al. Germline mutations in ATM and BRCA1/2 Distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol. 2017;71:740–747.
   PubMed Web of Science ®Google Scholar
• Mamidi TKK, Wu J, Hicks C. Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer. BMC Cancer. 2019;19:229–229.
   PubMed Web of Science ®Google Scholar
• Nicolosi P, Ledet E, Yang S, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5:523.
   PubMed Web of Science ®Google Scholar
• Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443–453.
   PubMed Web of Science ®Google Scholar
• Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer. 2007;109:518–527.
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration. FoundationOne CDx Technical Information 2017. [cited 2019 Jul 1] Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019C.pdf
   Google Scholar
• Zubeldia K, Romney GW. Anonymously linking a plurality of data records. United States Patent US 6,397,224. 2002 May 28.
   Google Scholar
• Ober NS, Grubmuller J, Farrell M, et al. System and method for generating de-identified health care data. United States Patent US 7,376,677. 2008 May 20.
   Google Scholar
• Saunders EJ, Dadaev T, Leongamornlert DA, et al. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Br J Cancer. 2016;114:945–952.
   PubMed Web of Science ®Google Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676–682.
   PubMed Web of Science ®Google Scholar
• Kolinsky M, Mateo J, Sumanasuriya S, et al. Clinical characteristics of metastatic castration-resistant prostate cancer (mCRPC) patients with DNA repair (DNAr) defects. JCO. 2016;34:5028–5028.
   Google Scholar
• Alemayehu B, Buysman E, Parry D, et al. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ. 2010;13:351–361.
   PubMedGoogle Scholar
• Mehra M, Wu Y, Dhawan R. Healthcare resource use in advanced prostate cancer patients treated with docetaxel. J Med Econ. 2012;15:836–843.
   PubMedGoogle Scholar
• Hagiwara M, Delea TE, Saville MW, et al. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Prostate Cancer Prostatic Dis. 2013;16:23–27.
   PubMed Web of Science ®Google Scholar
• Hu JC, Nguyen P, Mao J, et al. Increase in prostate cancer distant metastases at diagnosis in the United States. JAMA Oncol. 2017;3:705–707.
   PubMed Web of Science ®Google Scholar
• Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. JCO. 2010;28:1117–1123.
   PubMed Web of Science ®Google Scholar
• Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415–1424.
   PubMed Web of Science ®Google Scholar
• Abida W, Bryce AH, Vogelzang NJ, et al. Preliminary results from TRITON2: a phase 2 study of rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Ann Oncol. 2018;29:viii271–viii302.
   Web of Science ®Google Scholar
• Smith MR, Sandhu SK, Kelly WK, et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): preliminary results of GALAHAD. JCO. 2019;37:202.
   PubMedGoogle Scholar
• Goodall J, Mateo J, Yuan W, et al. Circulating Cell-Free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov. 2017;7:1006–1017.
   PubMed Web of Science ®Google Scholar
• Cheng HH, Sokolova AO, Schaeffer EM, et al. Germline and somatic mutations in prostate cancer for the clinician. JNCCN. 2019;17:515–521.
   Google Scholar
• Cheng Y, Wang S, Han L, et al. Concurrent somatic mutations in driver genes were significantly correlated with lymph node metastasis and pathological types in solid tumors. Oncotarget. 2017;8:68746–68757.
   PubMedGoogle Scholar
• Grellety T, Lucchesi C, Hostein I, et al. High-depth sequencing of paired primary and metastatic tumours: implications for personalised medicine. Eur J Cancer. 2017;84:250–256.
   PubMed Web of Science ®Google Scholar
• Yilmaz AS, Ozer HG, Gillespie JL, et al. Differential mutation frequencies in metastatic cutaneous squamous cell carcinomas versus primary tumors. Cancer. 2017;123:1184–1193.
   PubMed Web of Science ®Google Scholar
• Abida W, Armenia J, Gopalan A, et al. Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol. 2017;2017:1–26.
   Google Scholar